person · Reporting owner

Cajigas John

Disclosed activity across 1 company

Tapewire entity: 175977
SEC CIK: 0001582797

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
TANDEM DIABETES CARE INCTNDM · Entity 4682	EVP, CFO & TREASURER	May 15, 2017	May 18, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TANDEM DIABETES CARE INC

Report date May 15, 2017 · Filed May 18, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,353	Reported balance After 2017-05-15 transaction · row 1 1 source row Row 1 · 2017-05-15 · Grant · Acquired 10,831 · Balance 18,353 F1: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. 2013 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 16, 2016 through May 15, 2017. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on May 15, 2017.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.90	Direct	105,000	Reported balance After 2017-05-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-05-17 · Grant · Acquired 105,000 · Balance 105,000 F4: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F5: All shares subject to the option will vest as to 25% on 5/17/2018 and the remainder in 36 equal monthly installments thereafter. F6: The expiration date for these options is 10 years from the date of grant.
Common StockSEC Table I · non-derivative	IndirectSee footnote	41,463	Reported balance Holding disclosure · report date 2017-05-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 41,463 F3: The securities are held by the John Cajigas and Mary E. Cajigas Family Trust, dated 8/11/2005.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. 2013 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 16, 2016 through May 15, 2017. This transaction is also exempt under Rule 16b-3(c).

F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on May 15, 2017.

F3: The securities are held by the John Cajigas and Mary E. Cajigas Family Trust, dated 8/11/2005.

F4: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan.

F5: All shares subject to the option will vest as to 25% on 5/17/2018 and the remainder in 36 equal monthly installments thereafter.

F6: The expiration date for these options is 10 years from the date of grant.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 17, 2017 Filed May 18, 2017 21:01 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	GrantStock Options · Derivative	105,000	$0.00 Strike: $0.90	$0.00	Disclosure SEC source: 0001209191-17-033633 · doc4.xml · derivative · entry 3 Cajigas John · CIK 0001582797 · EVP, CFO & TREASURER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires not disclosed F4 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F5 · derivative.exercise_date: All shares subject to the option will vest as to 25% on 5/17/2018 and the remainder in 36 equal monthly installments thereafter. F6 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document
May 15, 2017 Filed May 18, 2017 21:01 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	GrantCommon Stock	10,831	$0.77	$8,339.87	Disclosure SEC source: 0001209191-17-033633 · doc4.xml · nonDerivative · entry 1 Cajigas John · CIK 0001582797 · EVP, CFO & TREASURER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,353 F1 · date: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. 2013 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 16, 2016 through May 15, 2017. This transaction is also exempt under Rule 16b-3(c). F2 · date: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on May 15, 2017. Read SEC document
December 16, 2016 Filed Dec 17, 2016 01:39 UTC	TANDEM DIABETES CARE INC TNDM · Entity 4682	GrantStock Options · Derivative	169,200	$0.00 Strike: $2.30	$0.00	Disclosure SEC source: 0001209191-16-155750 · doc4.xml · derivative · entry 1 Cajigas John · CIK 0001582797 · EVP, CFO & TREASURER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,200 Underlying: Common Stock · 169,200 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2 · derivative.exercise_date: All shares subject to the option will vest as to 50% on 12/16/2017 and the remainder in 12 equal monthly installments thereafter. F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.